PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma

PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma

Abstract Background Pazopanib, a multitargeted tyrosine kinase inhibitor, is recommended as the standard treatment for refractory soft tissue sarcoma (STS). However, there are comparatively few molecular determinants for predicting pazopanib efficacy. Based on correlative studies regarding the predi...

Full description

Bibliographic Details
Main Authors: Sang Kyum Kim, Jee Hung Kim, Seung Hyun Kim, Young Han Lee, Jung Woo Han, Wooyeol Baek, Ha Young Woo, Min Kyung Jeon, Hyo Song Kim
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Cancer
Subjects:
Soft tissue sarcoma
Pazopanib
PD-L1
Biomarker
Online Access:https://doi.org/10.1186/s12885-021-08069-z

Internet

https://doi.org/10.1186/s12885-021-08069-z

Similar Items